TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8600
-0.1800 (-4.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0400
Open3.9700
Bid3.8500 x 900
Ask3.9500 x 800
Day's Range3.8100 - 4.0900
52 Week Range2.5200 - 28.8000
Volume387,896
Avg. Volume743,468
Market Cap15.523M
Beta (3Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-8.2630
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire11 days ago

    Trovagene Receives Approximately $3.0 Million From Exercise of Warrants

    SAN DIEGO , March 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division ...

  • ACCESSWIRE11 days ago

    A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?

    The FDA recently took a big step towards blessing the emerging field of brain-computer interfacing technology, which has broad application in prosthetics and even enhancing the human brain. Visionaries like Elon Musk are betting on the latter happening quickly, and startups like his are designing software and hardware to capitalize on new technology breakthroughs. This field of neurology, sometimes known as neuromodulation, has only recently come into the pubic markets spotlight with companies like electroCore, Inc. (ECOR) and Nuvectra (NVTR) going public with technology that can assuage pain through electric stimulation of the nervous system.

  • PR Newswire12 days ago

    Trovagene Regains Compliance with Nasdaq Listing Requirements

    SAN DIEGO , March 12, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division ...

  • What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?
    Simply Wall St.16 days ago

    What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?

    In December 2018, TrovaGene, Inc. (NASDAQ:TROV) announced its most recent earnings update, which suggested that losses became smaller relative to the prior year's level as a result of recent tailwindsRead More...

  • TrovaGene News: Why TROV Stock Is Skyrocketing Today
    InvestorPlace16 days ago

    TrovaGene News: Why TROV Stock Is Skyrocketing Today

    Recent TrovaGene news continues to have TROV stock flying high for the second day in a row.Source: Shutterstock What has TrovaGene (NASDAQ:TROV) stock up today is its earnings report for the fourth quarter of 2018. The company released this earnings report after the markets closed on Wednesday. Included in the earnings report was an update concerning its drug onvansertib.Here's what was said by Chairman and CEO Dr. Thomas Adams in the TrovaGene news release.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Our AML trial continues to advance and data shows that the combination of onvansertib and standard-of-care chemotherapy is demonstrating both a favorable safety profile and showing activity in greater than 88% of evaluable patients treated to-date, which is very encouraging. In January, we received a 'study may proceed' notification from the FDA for our Phase 1b/2 trial in mCRC and expect that enrollment in this trial, which is being funded by PoC Capital, will begin mid-year."The positive TrovaGene news concerning onvansertib resulted in the stock increasing by about 31% on Thursday. It looks like this positive momentum is still carrying the stock to higher levels today. * 5 Airline Stocks In Serious Trouble The rest of the TrovaGene news release includes losses per share of $1.09 on revenue of $78,000 for the fourth quarter of the year. Wall Street was looking for losses per share of $1.05 during the quarter, but this didn't keep TROV stock down at all.TROV stock was up 74% as of Friday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks Already Rewarding Shareholders In 2019 * The 10 Best-Performing ETFs This Year * 7 Stocks That Should Be Worried About a Data Dividend As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post TrovaGene News: Why TROV Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • PR Newswire18 days ago

    Trovagene Announces Fourth Quarter and Full-Year 2018 Results

    SAN DIEGO , March 6, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division ...

  • PR Newswire24 days ago

    Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting

    SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division ...

  • PR Newswirelast month

    Trovagene, Inc. Announces Reverse Stock Split

    SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6 effective February 19, 2019 (the "effective Date"). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.

  • PR Newswirelast month

    Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference

    SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today presented an overview of its ongoing Phase 2 study evaluating Onvansertib in combination with Zytiga® (abiraterone acetate)/prednisone in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, CA.

  • PR Newswire2 months ago

    Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)

    SAN DIEGO, Jan. 29, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC Capital, LLC, to fund clinical development of Onvansertib, Trovagene's first-in-class, 3rd generation oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor in a Phase 1b/2 clinical trial in patients with metastatic Colorectal Cancer (mCRC). Trovagene submitted an Investigational New Drug (IND) application and protocol to the FDA on December 19, 2018, and received a "study may proceed" notification from the FDA, 28-days later, on January 16, 2019.

  • PR Newswire2 months ago

    Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer

    SAN DIEGO, Jan. 23, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced the issuance of a new patent (10,155,006), entitled Combination Therapies and Methods of Use Thereof for Treating Cancer, by the U.S. Patent and Trademark Office (USPTO). This patent broadens previously issued patent (9,566,280), by expanding the use of Onvansertib to encompass combination therapies with any anti-androgen and androgen antagonist drug, such as Zytiga, Xtandi and Erleada for the treatment of metastatic and non-metastatic castrate-resistant prostate cancer.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • ACCESSWIRE3 months ago

    Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib

    As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. Trovagene caught my attention after the company released data from a Phase 1b/2 clinical trial of Onvansertib for the treatment of patients with Acute Myeloid Leukemia (AML). Through the ongoing Phase 1b segment of the trial, the company is working to identify the maximum-tolerated dose of Onvansertib in patients with AML who are ineligible for induction therapy or who have relapsed or refractory disease.

  • PR Newswire4 months ago

    New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML

    SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today presented updated data from its ongoing Phase 1b/2 study evaluating Onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML). The data, featured in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, demonstrate that Onvansertib, in combination with LDAC or decitabine, even at the dose-escalation phase of the trial, is benefiting patients who have relapsed/refractory Acute Myeloid Leukemia (AML), and that the combination regimen is safe and well-tolerated, with no serious adverse events (SAEs) reported to-date.

  • What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?
    Simply Wall St.4 months ago

    What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?

    TrovaGene Inc (NASDAQ:TROV), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is TROV will Read More...

  • PR Newswire4 months ago

    Trovagene, Inc. Receives Positive Nasdaq Listing Decision

    SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 bid price requirement. "I am pleased that the Nasdaq Hearing Panel responded favorably," said Dr. Thomas Adams, Executive Chairman of Trovagene.

  • PR Newswire4 months ago

    Trovagene Announces Launch of New Company Website

    SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced the launch of its newly revamped website. This redesigned website offers easy access to essential information, while providing a more detailed understanding of the Company's approach to, and advances in, the clinical development of its targeted cancer therapeutic, Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor.

  • PR Newswire5 months ago

    Trovagene Announces Third Quarter 2018 Highlights and Financial Results

    SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) ...

  • PR Newswire5 months ago

    Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting

    SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that its abstract highlighting data from the Company's lead clinical program in Acute Myeloid Leukemia (AML) has been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018.

  • PR Newswire5 months ago

    Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office

    New patent claims strengthen patent estate revenue Aligns with Onvansertib Clinical Development and Biomarker Strategy in AML SAN DIEGO , Oct. 24, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a ...

  • PR Newswire5 months ago

    Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018

    -Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics ...

  • ACCESSWIRE5 months ago

    Trovagene Advances its Clinical Development of PCM-075, Analysts review and Target

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: GTx and TrovaGene

    NEW YORK, NY / ACCESSWIRE / October 8, 2018 / GTx Inc. was seeing big gains on Friday despite any news. The company had recently saw its shares collapse on news that its only drug candidate had failed a mid-stage clinical trial. Shares of TrovaGene Inc. were also in the green despite any news on Friday, but it was last week that the company announced it had entered into an exclusive patent license agreement with the Massachusetts Institute of Technology.